Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Enjuvia
Synthetic Conjugated estrogens, B · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Synthetic Conjugated estrogens, B | DRUG | 1 (0.3mg) tablet daily |
| Placebo | OTHER | 1 tablet daily |
Inclusion Criteria: * Naturally or surgically postmenopausal * Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse) Exclusion Criteria: * Known sensitivity or contraindication to estrogens or progestins * History or current diagnosis of endometria...
Synthetic Conjugated estrogens, B is used to treat menopause-related conditions, specifically vulvovaginal atrophy. It is a small molecule estrogen therapy developed by Teva Pharmaceutical Industries Limited. The Phase 3 program evaluated a 0.3 mg dose in postmenopausal women aged 30 years and older in the United States.
Synthetic Conjugated estrogens, B targets the estrogen receptors ESR1 and ESR2 as an agonist. By activating these receptors, the drug produces estrogenic effects relevant to menopausal symptoms such as vulvovaginal atrophy. Both receptors are members of the nuclear receptor family that mediate estrogen signaling in reproductive and other tissues.
Synthetic Conjugated estrogens, B is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program for this estrogen therapy in menopause.
Synthetic Conjugated estrogens, B is in Phase 3 development. The single registered trial, NCT00196378, has been completed. The drug is investigational and is not described as approved. The Phase 3 study was randomized, double-blind, and placebo-controlled, enrolling 300 female participants.
Synthetic Conjugated estrogens, B has been studied in one clinical trial, NCT00196378, titled A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy. The Phase 3 trial is completed, enrolled 300 participants, and was conducted in the United States.
Yes, Synthetic Conjugated estrogens, B is also known as Enjuvia. The Phase 3 trial NCT00196378 evaluated Enjuvia 0.3 mg for the treatment of vulvovaginal atrophy in menopausal women. Enjuvia is the brand name used for this Teva Pharmaceutical Industries Limited product.